BXPHFBotanix Pharmaceuticals Limited
This year, BXPHF has to prove it’s more than a speculative token — the next catalyst is a strategic capital raise & buyout on 2026-10-15, which models a bull target of $0.02 (65% lean) or a bear fallback of $0.01. The outcome hinges on whether the company can secure meaningful capital or attract a buyer, both of which would signal a shift from speculative hype to real value creation.
The schedule
- Thu15Oct
Strategic capital raise and buyout activity expected to impact market sentiment and liquidity.
Past
- Tue15Sep
Actual outcome: Bear · $0.01 at outcome
The company reported an EPS actual of -0.0153, matching the estimate, but the stock fell to the bear floor of $0.01. The lack of positive guidance and weak forward outlook likely pressured the price, despite the earnings beat.
Earnings release and operating update for Q3 2026, with potential guidance on future performance and strategic initiatives.
- Fri28Aug
Actual outcome: Mixed · $0.01 at outcome
The stock remained flat following the FY26 results as the EPS matched expectations. However, the lack of clear guidance and weak forward-looking commentary failed to inspire confidence, resulting in minimal price movement.
Quarterly financial results and earnings call with management.
